Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02931253 · ClinicalTrials.gov registry record · Phase 2
Metformin as an Upstream Therapy in Atrial Fibrillation
A Phase 2 study, sponsored by The Guthrie Clinic.
- Terminated
- Registry status
- Phase 2
- Development phase
- 6
- Enrollment target
NCT02931253 is a Phase 2 study that was terminated before completion, run by The Guthrie Clinic. The registered enrollment target is 6 participants.
The verdict
NCT02931253, a Phase 2 study, was terminated before completion, sponsored by The Guthrie Clinic.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 6 participants
- Enrollment target
Study Summary
The purpose of this study is to see if the study drug metformin will help patients who are overweight and have atrial fibrillation. This study aims to see if metformin helps patients stay in normal sinus rhythm after a catheter ablation. Metformin is investigational for use in patients with atrial fibrillation. Metformin is approved by the Food and Drug Administration (FDA) for use in patients with type 2 Diabetes Mellitus. Metformin is used with a proper diet and exercise program to control high blood sugar, and has been shown to help people lose weight. This study aims to look at the effects of metformin on weight loss and heart rhythm in patients with atrial fibrillation.
Interventions
- DRUG Metformin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 6 participants |
| Start Date | 2017-04-11 |
| Est. Completion | 2018-07-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02931253
The ClinicalTrials.gov registry entry for NCT02931253 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 6 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is The Guthrie Clinic, which has 17 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Metformin is the first listed.
NCT02931253 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02931253 about?
NCT02931253 is a clinical study titled "Metformin as an Upstream Therapy in Atrial Fibrillation". The purpose of this study is to see if the study drug metformin will help patients who are overweight and have atrial fibrillation. This study aims to see if metformin helps patients stay in normal sinus rhythm after a catheter ablation. Metformin is investigational for use in patients with atrial ...
What is the current status of trial NCT02931253?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 6 participants. The study started on 2017-04-11. Estimated completion is 2018-07-10.
What interventions are being tested in trial NCT02931253?
The interventions under investigation include: Metformin (DRUG).
Who is sponsoring clinical trial NCT02931253?
This trial is sponsored by The Guthrie Clinic, which has 17 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.